NCT04604652View on ClinicalTrials.gov

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Primary Biliary CholangitisPrimary Biliary CirrhosisCholangitisCholestasisBiliary Tract DiseasesBile Duct Stricture
Interventions
DRUG

HTD1801 (BUDCA)

HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.

Trial Locations (12)

11030

Northshore University Hospital, Manhasset

23226

Bon Secours Liver Institute of Richmond, Richmond

23602

Liver Institute of Virginia, Newport News

30309

Piedmont Healthcare, Atlanta

33136

University of Miami Schiff Center for Liver Disease, Miami

48202

Henry Ford Health Services, Detroit

63104

St. Louis University, St Louis

75246

Baylor Research Institute, Dallas

78215

The Texas Liver Institute, San Antonio

98105

Liver Institute Northwest, Seattle

02114

Massachusetts General Hospital, Boston

02905

University GI, Providence

All Listed Sponsors
lead

HighTide Biopharma Pty Ltd

INDUSTRY